The Health Ministry received on Wednesday an updated Healthcare Basket list for the upcoming year, which appears to include more drugs for diabetics but less for cancer patients.
The medical services basket is a list of government subsidies that encompasses the entire range of services, drugs, medical equipment and devices that insured members of the public are eligible to receive.
After four months of deliberations, an expert panel has submitted to Health Minister Yuli Edelstein and Health Ministry Director-General Prof. Hezi Levy a list of 117 drugs and technologies, including various medical treatments that will serve over 169,000 Israelis, at an estimated cost of NIS 550 million.
Overall, the panel had received submissions for some 880 different medicines and treatments at a total cost of more than NIS 3 billion.
Among the latest drugs that have been approved for diabetics are Trulicity, Bydureon, Victoza and Lixisenatide.
One panel member said that the expansion of available treatments for diabetics is meant to make them more accessible for more than half a million Israelis who live with the chronic condition.
"So far, the treatments for diabetes were very limited. Many patients need them, but the basket only allowed patients suffering from severe cases of diabetes to get them," he said.
"This is the most widely common chronic condition in the country, and it has very serious health repercussions, and the basket did not provide adequate treatment for it so far."
The only drug approved in the field of mental health is Rexulti which is used to treat schizophrenia patients.
The use of the emergency contraception drug Levonorgestrel (marketed in Israel under the brand name Postinor), which was so far provided only to victims of sexual assault, will now also include emergency contraception for women aged 20 and under.